Positive Topline Results for Cannabinoid-Based Med for Nerve Pain

An experimental, proprietary cannabinoid-based drug in development for diabetic neuropathy outperformed pregabalin in a clinical trial, achieving significant reduction in pain severity, new topline results released by Zelira Therapeutics suggest.

"The implications of these results for patients are incredibly promising," principal investigator Bryan Doner, DO, medical director of HealthyWays Integrated Wellness Solutions, Gibsonia, Pennsylvania, said in a news release.

"Through this rigorously designed study, we have demonstrated that ZLT-L-007 is a safe, effective, and well-tolerated alternative for patients who would typically seek a pregabalin -level of pain relief," he added.

The company plans to report additional insights from the full study, as they become available, during fiscal year 2023-2024.

Source: MEDspace